Retina (Philadelphia, Pa.) · 2025
The Efficacy and Safety of Intravenous Prostaglandin E1 in the Management of Retinal Artery Occlusion: A Systematic Review.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Serhan Hashem Abu, Oweidah Ahmed, Shaheen Abdulla, Emoush Laith O, Mahmoud Abdullah Bin, Al-Nawaflh Mutaz, Elnahry Ayman G
Аннотация
PURPOSE: To evaluate the efficacy and safety of prostaglandin E1 (PGE1) for the management of central/branch retinal artery occlusion (CRAO/BRAO).
METHODS: Our protocol was registered prospectively on PROSPERO (CRD42024522961). We searched 4 electronic databases [PubMed, Scopus, Web of Science, and Google Scholar] to retrieve all studies reported using PGE1 for patients with CRAO/BRAO. We conducted a Wilcoxon signed-rank test to assess the effect of PGE1 on the visual acuity (VA) of included subjects. VA change was utilized as a measure to assess the degree of VA improvement. We assessed the quality of included studies using the JBI tool.
RESULTS: We included a total of 6 studies with a total of 21 cases. Age ranged from 45 to 97 years with a mean of 65.76 years for 10 females and 11 males. Cases with CRAO represented 85.7% and BRAO represented 14.3% of total cases. The median time from symptoms onset to treatment initiation was 7 hours. The median for the initial dose was 40 μg. Wilcoxon signed-rank test revealed significant improvement in visual acuity after intravenous PGE1 treatment (V = 231, p < 0.05).
CONCLUSION: Our analysis revealed preliminary evidence suggesting that IV PGE1 may be a potentially safe and effective treatment for improving VA in patients with CRAO/BRAO. However, our evidence is limited as our review relies primarily on case reports and case series.
METHODS: Our protocol was registered prospectively on PROSPERO (CRD42024522961). We searched 4 electronic databases [PubMed, Scopus, Web of Science, and Google Scholar] to retrieve all studies reported using PGE1 for patients with CRAO/BRAO. We conducted a Wilcoxon signed-rank test to assess the effect of PGE1 on the visual acuity (VA) of included subjects. VA change was utilized as a measure to assess the degree of VA improvement. We assessed the quality of included studies using the JBI tool.
RESULTS: We included a total of 6 studies with a total of 21 cases. Age ranged from 45 to 97 years with a mean of 65.76 years for 10 females and 11 males. Cases with CRAO represented 85.7% and BRAO represented 14.3% of total cases. The median time from symptoms onset to treatment initiation was 7 hours. The median for the initial dose was 40 μg. Wilcoxon signed-rank test revealed significant improvement in visual acuity after intravenous PGE1 treatment (V = 231, p < 0.05).
CONCLUSION: Our analysis revealed preliminary evidence suggesting that IV PGE1 may be a potentially safe and effective treatment for improving VA in patients with CRAO/BRAO. However, our evidence is limited as our review relies primarily on case reports and case series.